News

ASGCT 2026: In vivo anti-BCMA CAR-T for the treatment of plasma cell disorders

ASGCT 2026: Targeted Lipid Nanoparticle-Mediated In Vivo Delivery of Anti-CD19 and Anti-CD20 Surrogate-CAR mRNA Drives Potent B Cell Depletion in Mice and Primates

ASH 2025: In Vivo Generation of Anti-CD19 CAR-T Cells for the Treatment of B Cell-Mediated Autoimmune Diseases

American Conference on Pharmacometrics 2025: Semi-Mechanistic Model of LNP-Mediated in Vivo CAR-T Cell Engineering in Primates

10th Annual CAR/TCR Summit: In Vivo CAR-T Cell Engineering Using a Targeted LNP (AERA-109) Enables Deep B Cell Depletion Without Conditioning

ASGCT 2025: In Vivo Generation of CAR-T Cells for the Treatment of B Cell-Mediated Autoimmune Diseases

Top